Last updated: May 2, 2026
What is Diclegis and what’s the current regulatory footprint?
Diclegis is a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine (vitamin B6) 10 mg, marketed in the US for nausea and vomiting of pregnancy (NVP). It is the branded version of delayed-release doxylamine/pyridoxine (later-line spelling: doxylamine succinate and pyridoxine hydrochloride in US labeling).
Key US labeling constructs
- Indication: Treatment of NVP in pregnant patients.
- Dosage form: Delayed-release tablets.
- Dose titration approach: Label-directed stepwise titration across several days depending on symptom response.
- Safety signals in pregnancy: Managed through labeling warnings around sedation, anticholinergic effects, and fetal exposure context consistent with established antihistamine and vitamin use in pregnancy. (US label data.) [1]
Regulatory status and exclusivity context
- Diclegis is an FDA-approved branded product; no new NDA approvals are indicated in the record cited below for 2022-2025 based on FDA label access data. [1]
- The manufacturer’s branding and label access indicate ongoing marketed availability and distribution through current label versions. [1]
What clinical-trial activity is visible for Diclegis (doxylamine/pyridoxine) in the public record?
Across major public registries, the clinical-trial visibility for Diclegis specifically is dominated by:
- Historical comparative studies and formulation-related or regimen-related investigations conducted around initial adoption, and
- Limited contemporary interventional trials that generally do not present large-scale, late-stage registrational programs for the same fixed combination in the US.
Registry visibility (what matters for investment and R&D)
- ClinicalTrials.gov: searches and record patterns show that doxylamine/pyridoxine studies are mostly earlier-generation and/or non-dedicated (class-level or regimen-level) unless a new formulation, dosing schedule, or comparator arm is introduced. This reduces the signal for a fresh late-stage Diclegis-specific development thesis based purely on registry volume. [2]
- PubMed scientific activity: literature activity remains present, but much of it is clinical practice data, observational evidence, and guideline synthesis rather than new pivotal trials tied to the Diclegis brand. [3]
Practical implication for forecasting
- A Diclegis-focused market growth thesis in 2025-2035 is less dependent on new registrational readouts and more dependent on share shifts (generic penetration vs branded retention), guideline adoption, payer behavior, and US patient capture. (This is consistent with the absence of a prominent late-stage Diclegis brand revival signal in the public interventional record.) [1-3]
How does Diclegis compete in NVP and what do guidelines imply for demand?
Diclegis sits in the first-line NVP treatment space where doxylamine/pyridoxine is often included among recommended options.
Evidence base used by clinicians and payers
- ACOG practice guidance and other pregnancy symptom frameworks generally support the use of doxylamine-based regimens and vitamin B6 strategies as part of stepwise management. [4]
- Systematic review and meta-analysis data for NVP interventions supports benefit for doxylamine/pyridoxine regimens versus placebo and helps establish ongoing clinical uptake for this class even as branded competitors face generic entry dynamics. [3]
Competitive set
- Branded Diclegis versus generic doxylamine/pyridoxine delayed-release and other NVP regimens (including alternative antiemetics used after first-line failure).
- Primary battleground: Formulary access and patient adherence to delayed-release titration schedules.
Market analysis: What are the key commercial drivers and constraints for Diclegis?
Core demand drivers (2025 baseline)
- Prevalence of NVP: NVP affects a large share of pregnancies, creating a broad addressable population for first-line therapy.
- Guideline alignment: doxylamine/pyridoxine regimens remain guideline-supported for stepwise NVP care. [4]
- Physician prescribing inertia: once a delayed-release doxylamine/pyridoxine regimen is established in a practice, switching costs for prescribers can be low but payer constraints can dominate.
Constraints that cap branded growth
- Generic competition pressure
- Once generics of delayed-release doxylamine/pyridoxine are available (and placed on formularies), branded pricing power compresses.
- Payer step edits
- Plans frequently apply prior authorization, quantity limits, or step therapy moving patients from OTC B6 strategies or generic doxylamine/pyridoxine to brand only after non-response.
- Titration-based adherence
- Delayed-release regimens require follow-through across dose escalation; real-world adherence can be lower than trial adherence.
Demand stabilization factors for the branded brand
- Even under generic entry, branded products can hold share through:
- Formulary preference tiers (where negotiated),
- Supply continuity and patient support programs, and
- Perceived efficacy and tolerability consistency.
2025-2035 projection: What trajectory is most realistic for Diclegis?
The projection below models the market outcome where:
- Branded Diclegis faces ongoing generic substitution,
- Class demand remains supported by guidelines and evidence, and
- Market growth comes mostly from pregnancy volume growth and improved capture in treated NVP patients, partially offset by price erosion and tiering.
Projection framework (what moves the curve)
- Unit demand (patients treated): increases with births and greater treatment capture.
- Net sales (brand revenue): declines or grows slowly depending on:
- branded share erosion,
- rebate compression,
- plan tier placement.
Base-case forecast (US only; branded Diclegis)
Because the prompt does not provide a current Diclegis sales base year, this forecast uses a relative pathway rather than claiming a specific dollar starting point. The directional profile is driven by known branded-versus-generic dynamics in NVP fixed-dose combinations, guideline support, and label-driven use.
Assumed path for branded share and pricing (directionally consistent)
- 2025-2027: Branded share continues to erode as formularies consolidate around generics. Net price per Rx continues down via rebates and tiering.
- 2028-2031: Share stabilizes at a lower branded floor due to persistence in some payer networks and patient continuity.
- 2032-2035: Branded growth is limited to episodic formulary renegotiations and incremental treatment capture, offset by continued generic substitution.
Outcome projection (directional)
- US branded Diclegis net sales: flat to low-single-digit decline through the late 2020s, transitioning to near-flat by the early 2030s as the residual share base stabilizes.
- US total class market (doxylamine/pyridoxine delayed-release): low to mid-single-digit growth through the period, driven by pregnancy volume and capture improvements, but with ongoing price compression.
This profile aligns with:
- persistent clinical and guideline support for doxylamine/pyridoxine regimens, [4]
- evidence of ongoing clinical use of the class, [3]
- absence of a prominent registrational Diclegis-specific escalation signal in public trial records. [2]
What could change the projection materially (upside and downside)?
Upside triggers (limited but real)
- New evidence strengthening delayed-release regimen preference in clinical protocols (guideline revisions or payer clinical criteria) increases capture.
- Reimbursement improvements for branded product in key PBM formularies.
Downside triggers (more likely)
- Further formulary tightening that routes patients to generics earlier in the step-therapy sequence.
- Therapeutic substitution toward alternative first-line or second-line agents if protocols shift away from doxylamine-based delayed-release schedules.
How should investors and R&D teams interpret the clinical and commercial picture?
Investment implications
- Diclegis is a mature branded asset in a first-line pregnancy symptom class where the market is structurally shaped by generics, payers, and adherence to stepwise titration.
- The credible growth story for a brand-holder is typically share defense, not new clinical differentiation.
R&D implications
- If a new program is contemplated in NVP, the more investable angles tend to be:
- improved tolerability profiles (sedation mitigation),
- adherence improvements (simplified dosing),
- or differentiated delivery (without changing the established pharmacologic backbone).
- Without a new registrational trial signal in the public record for Diclegis, the near-term “incremental trials” pathway is less likely to translate into a major market repricing. [2]
Key Takeaways
- Diclegis is FDA-approved delayed-release doxylamine/pyridoxine for nausea and vomiting of pregnancy with a mature label and established clinical use. [1]
- Public clinical-trial visibility shows limited modern, brand-specific late-stage momentum; most activity is historical or class-level rather than a fresh Diclegis registrational push. [2]
- Market growth for the drug’s therapy class should track pregnancy volume and guideline-supported capture, while branded revenue is constrained by generic substitution and payer tiering. [3][4]
- For 2025-2035, the most realistic branded trajectory is flat to low-single-digit decline transitioning to near-flat by the early 2030s, while the broader doxylamine/pyridoxine delayed-release class shows low to mid-single-digit growth with price compression.
FAQs
1) Is Diclegis still the standard first-line therapy for NVP in the US?
It remains part of guideline-supported stepwise NVP management pathways alongside vitamin and antihistamine-based strategies. [4]
2) Does the public clinical-trial record show new pivotal Diclegis results in recent years?
Public registry activity is present but does not show a prominent contemporary Diclegis-specific late-stage registrational program signal in the referenced sources. [2]
3) What drives branded Diclegis revenue most: prescriptions or pricing?
Branded revenue is typically more sensitive to net pricing via rebates/tiering once generics enter and to formulary access that governs prescription routing.
4) What is the main competitive pressure on Diclegis?
Generic delayed-release doxylamine/pyridoxine and formularies that steer NVP patients earlier to generics.
5) What is the main downside risk to Diclegis market share?
Tightening of step edits and earlier routing to generics, plus substitution toward alternative antiemetic protocols if guidelines or payer criteria shift.
References
[1] U.S. Food and Drug Administration. (n.d.). Diclegis (doxylamine succinate and pyridoxine hydrochloride) prescribing information / label. FDA. https://www.accessdata.fda.gov/
[2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: doxylamine pyridoxine studies (Diclegis and related regimens). https://clinicaltrials.gov/
[3] PubMed. (n.d.). Search results: doxylamine pyridoxine nausea and vomiting of pregnancy systematic review/meta-analysis. https://pubmed.ncbi.nlm.nih.gov/
[4] American College of Obstetricians and Gynecologists. (n.d.). Practice guidance on nausea and vomiting of pregnancy (NVP). https://www.acog.org/
